These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2091689)

  • 1. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of desferrioxamine infusion on red blood cell aluminum.
    Umeda M; Umimoto K; Tsurusaki K; Izumi N; Kishimoto T; Maekawa M
    ASAIO Trans; 1988; 34(3):297-9. PubMed ID: 3196524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
    Navarro JA; Granadillo VA; Rodríguez-Iturbe B; García R; Salgado O; Romero RA
    Clin Nephrol; 1991 May; 35(5):213-7. PubMed ID: 1855329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis.
    Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T
    ASAIO Trans; 1986; 32(1):52-7. PubMed ID: 3778761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population.
    Yuan B; Klein MH; Contiguglia RS; Mishell JL; Seligman PA; Miller NL; Molitoris BA; Alfrey AC; Shapiro JI
    Ren Fail; 1989; 11(2-3):91-6. PubMed ID: 2623200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trace elements and complications in patients undergoing chronic hemodialysis.
    Hosokawa S; Oyamaguchi A; Yoshida O
    Nephron; 1990; 55(4):375-9. PubMed ID: 2392189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 9. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
    Coburn JW; Norris KC
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):12-21. PubMed ID: 3299588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy.
    Leung FY; Hodsman AB; Muirhead N; Henderson AR
    Clin Chem; 1985 Jan; 31(1):20-3. PubMed ID: 3965214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients.
    Huang JY; Wu MS; Wu CH
    Ren Fail; 2001 Nov; 23(6):789-95. PubMed ID: 11777318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of anaemia with desferrioxamine in haemodialysis patients.
    Praga M; Andrés A; de la Serna J; Ruilope LM; Nieto J; Estenoz J; Millet VG; Arnaiz F; Rodicio JL
    Nephrol Dial Transplant; 1987; 2(4):243-7. PubMed ID: 3118265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipofuscin products, lipid peroxides and aluminum accumulation in red blood cells of hemodialyzed patients.
    Jain SK; Abreo K; Duett J; Sella ML
    Am J Nephrol; 1995; 15(4):306-11. PubMed ID: 7573188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferoxamine and coated charcoal hemoperfusion to remove aluminum in dialysis patients.
    McCarthy JT; Milliner DS; Schmidt DF; Schniepp BJ; Kurtz SB; Johnson WJ
    Kidney Int; 1988 Dec; 34(6):804-8. PubMed ID: 3210542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
    Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.